Identifying Drivers of First-line HR+/HER2- Metastatic Breast Cancer Treatment Choices

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jun 11

PMID 38861295

Authors

Adam Brufsky

Martine C Maculaitis

Lewis Kopenhafer

Patrick Olsen

Samantha K Kurosky

Lillian Shahied Arruda

Wendy Heck

Ashley S Cha-Silva

Affiliations

Soon will be listed here.

Abstract

: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics.: Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42).: Efficacy and safety/tolerability were most important to 1L decision-making. Clinical characteristics corresponded with CDK4/6i and chemotherapy use. Anticipated compliance was associated with AI monotherapy use.

References

Nattinger A, Pezzin L, McGinley E, Charlson J, Yen T, Neuner J . Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus. 2015; 4:54. PMC: 4320689. DOI: 10.1186/s40064-015-0827-8. View

Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E . Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia Pac J Clin Oncol. 2018; 14 Suppl 4:3-11. DOI: 10.1111/ajco.13064. View

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Hart L . Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022; 386(10):942-950. DOI: 10.1056/NEJMoa2114663. View

Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri V . Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022; 7(2):100409. PMC: 8886005. DOI: 10.1016/j.esmoop.2022.100409. View

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S . Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast. 2016; 31:114-120. DOI: 10.1016/j.breast.2016.10.021. View

Papautsky E, Hamlish T . Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat. 2020; 184(1):249-254. PMC: 7415197. DOI: 10.1007/s10549-020-05828-7. View

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M, Andre F . 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12):1623-1649. PMC: 7510449. DOI: 10.1016/j.annonc.2020.09.010. View

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L . Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2020; 112(11):1089-1097. PMC: 7669227. DOI: 10.1093/jnci/djaa071. View

Park Y, Kim T, Kim G, Kang S, Park I, Kim J . Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2.... Lancet Oncol. 2019; 20(12):1750-1759. DOI: 10.1016/S1470-2045(19)30565-0. View

10.

Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K . Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20):1925-1936. DOI: 10.1056/NEJMoa1607303. View

11.

Elfgen C, Bjelic-Radisic V . Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. Cancers (Basel). 2021; 13(23). PMC: 8656925. DOI: 10.3390/cancers13235994. View

12.

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos E . Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2021; 32(4):488-499. DOI: 10.1016/j.annonc.2020.12.013. View

13.

. 2022 Snapshot: State of the Oncology Workforce in America. JCO Oncol Pract. 2022; 18(5):396. DOI: 10.1200/OP.22.00168. View

14.

Mahtani R, Vogel C . Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Manag Res. 2019; 11:513-524. PMC: 6324609. DOI: 10.2147/CMAR.S186658. View

15.

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

16.

Rugo H, Brufsky A, Liu X, Li B, McRoy L, Chen C . Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022; 8(1):114. PMC: 9553912. DOI: 10.1038/s41523-022-00479-x. View

17.

Lee S, Im S, Kim G, Jung K, Kang S, Park I . Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers (Basel). 2020; 12(11). PMC: 7694364. DOI: 10.3390/cancers12113265. View

18.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View

19.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

20.

Partridge A, Rumble R, Carey L, Come S, Davidson N, Di Leo A . Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014; 32(29):3307-29. PMC: 6076042. DOI: 10.1200/JCO.2014.56.7479. View